藥物基因體學於個人化醫療所扮演的角色

本報告已在2011年12月21日停止出版。

簡介

目錄

Abstract

The pharmaceutical industry is very gradually moving away from the blockbuster model of drug development to a model whereby medicines are designed to treat the specific patient, not the population as a whole. This trend is known as personalized medicine. Pharmacogenomics, which determines how genomic variations in people modify the behavior of drugs, will facilitate the development of personalized medicine. In this report, we examine how the use of pharmacogenomics will affect today's drug development strategies. We discuss many of the economic considerations now facing the industry in deciding whether or not to embrace pharmacogenomics in personalized medicine. Our Spectrum Expert Commentary addresses the attitudes of Americans on these issues.

Table of Contents

• Contents The Personalization of Medicine
• Pharmacogenomics
  • Defined
  • Drug Efficacy
  • Bronchodilators
  • Gefitinib and Erlotinib
  • Trastuzumab
  • Drug Metabolism
• The Economics of Personalized
  • Medicine
  • Pharmacogenomics' Impact on Clinical Trial Costs
  • Case History: deCODE Genetics' Use of Pharmacogenomics in Heart Attack Trials
  • Pharmacogenomics' Impact on Drug Revenues and Markets
  • Pharmacogenomics' Impact on the Blockbuster Model of Drug Development
  • Pharmacogenomics' Impact on Other Commercial Strategies
• Case Study: Treatment of Ten Hypothetical Patients With and Without Pharmacogenomic
  • Testing
  • Recent Pharmacogenomic Deals and Alliances
  • Regulatory Initiatives to Support the Use of Pharmacogenomics in Drug Development
  • United States
• Americans' Attitudes Toward Pharmacogenomics and Personalized Medicine
  • Europe
  • Japan
  • Outlook
  • The Public's Perspective
  • Pricing and Reimbursement
  • Development of Diagnostic Tests

• Figure 1 Application of Pharmacogenomics and Effects on Drug Responses
• Figure 2 Potential Impact of Pharmacogenomics on Drug Revenues, Gains, and Losses Figure 3 Maintaining Revenues in a Pharmacogenomic Era
• Figure 4 Pharmacogenomics: Potential Effect on Drug Development Costs
• Figure 5 Rapidly Increasing Use of Pharmacogenomics Information in New Drug Labels, 1945-2005
• Figure 6 Worldwide Projected Sales of Trastuzumab (Herceptin), 2005-2010 (millions of U.S. dollars)
• Table 1 Lowering Clinical Development Costs Using Pharmacogenomics: Potential to Reduce Costs by 25-45%
• Table 2 Diagnosis and Treatment Revenues for Ten Patients With and Without Genomic Testing
• Table 3 Clinical Data's Acquisitions in the Fields of Pharmacogenomics and Molecular Diagnostics, 2005-2006
• Table 4 Gene Logic: Select Pharmacogenomics Collaborations
• Table 5 deCODE Genetics: Select Pharmacogenomic Collaborations
• Table 6 FDA Guidance for Pharmacogenomic Data Submissions, March 2005

相關商品

以基因為基之藥物開發相關市場調查報告書

分子診斷﹕技術˙市場˙企業
Molecular Diagnostics - Technologies, Markets and Companies
價格 : US $ 5500
出版日期 : 2012年01月

蛋白質體﹕技術˙市場˙企業
Proteomics - Technologies, Markets and Companies
價格 : US $ 5000
出版日期 : 2012年01月

RNAi（RNA干擾）：技術、市場、企業
RNAi - technologies, markets and companies
價格 : US $ 4000
出版日期 : 2012年01月

Decision Resources, Inc.發行的生物科技相關市場調查報告書

以生物標記來預測自體免疫疾病生物療法的反應

Special Report: Use of Biomarkers to Predict Response to Biologics Therapy in Autoimmune Diseases

價格 : US $ 9200

出版日期 : 2011年06月

成為下一波一鳴驚人藥物的新一代治療用抗體的尋求

Pursuing Next-Generation Therapeutic Antibodies as the Next Source of Blockbuster Drugs

價格 : US $ 4600

出版日期 : 2011年06月

探索讓個人化醫療進化的資訊技術工具

Exploiting Information Technology Tools to Advance Personalized Medicine

價格 : US $ 4600

出版日期 : 2011年05月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!